Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.
Bram VerstocktSare VerstocktBrecht CreynsSophie TopsGert Van AsscheAnn GilsJan L CeuppensSéverine VermeireMarc FerranteChristine BreynaertPublished in: Alimentary pharmacology & therapeutics (2019)
Increased mucosal IL13RA2 expression is associated with an increased mucosal TNF burden in CD patients. In view of its specificity for prediction of anti-TNF therapy resistance, mucosal IL13RA2 expression is a potential biomarker for therapy selection and/or for the need of increased anti-TNF drug dosing.
Keyphrases
- rheumatoid arthritis
- poor prognosis
- ulcerative colitis
- disease activity
- end stage renal disease
- ankylosing spondylitis
- ejection fraction
- newly diagnosed
- binding protein
- stem cells
- long non coding rna
- emergency department
- interstitial lung disease
- peritoneal dialysis
- risk factors
- replacement therapy
- hidradenitis suppurativa